ADAR1 Capital Management logo

ADAR1 Capital Management

Description

ADAR1 Capital Management is an investment firm.

Investor Profile

ADAR1 Capital Management has backed more than 10 startups, with 8 new investments in the last 12 months alone. The firm has led 0 rounds, about 0% of its total and boasts 6 exits across its portfolio.

Investment Focus Highlights

  • Concentrates on Post Ipo Equity, Series C, Series A rounds (top funding stages).
  • Majority of deals are located in United States.
  • Strong thematic focus on Biotechnology, Health Care, Therapeutics.

Stage Focus

  • Post Ipo Equity (80%)
  • Series C (10%)
  • Series A (10%)

Country Focus

  • United States (100%)

Industry Focus

  • Biotechnology
  • Health Care
  • Therapeutics
  • Life Science
  • Medical
  • Pharmaceutical
  • Genetics
  • Robotics
  • Health Diagnostics
  • Biopharma
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does ADAR1 Capital Management frequently co-invest with?

BP
North America, California, United States, San Francisco
Co-Investments: 1
Nantahala Capital Management
North America, Connecticut, United States, New Canaan
Co-Investments: 3
Venrock Healthcare Capital Partners
North America, California, United States, Palo Alto
Co-Investments: 1
Co-Investments: 1
Frazier Life Sciences
North America, California, United States, Menlo Park
Co-Investments: 2
RA Capital Management
North America, Massachusetts, United States, Boston
Co-Investments: 3
VC
North America, Georgia, United States, Alpharetta
Co-Investments: 1
SC
North America, Oregon, United States, Bend
Co-Investments: 2
Co-Investments: 2
Janus Henderson Investors
Europe, England, United Kingdom, London
Co-Investments: 4

What are some of recent deals done by ADAR1 Capital Management?

atai Life Sciences

Munich, Bayern, Germany

Atai Life Sciences develops innovative mental health treatments that address significant unmet medical needs.

BiotechnologyLife ScienceMental HealthNeuroscienceTherapeutics
Post Ipo EquityJul 1, 2025
Amount Raised: $50,000,000
Quince Therapeutics

South San Francisco, California, United States

Quince Therapeutics is developing treatments for Alzheimer's and other degenerative disorders.

BiotechnologyHealth CareMedicalPharmaceuticalTherapeutics
Post Ipo EquityJun 12, 2025
Amount Raised: $22,000,000
LEXEO Therapeutics

New York, New York, United States

LEXEO Therapeutics utilizes gene therapy to treat genetically defined cardiovascular and central nervous system diseases.

BiotechnologyLife ScienceTherapeutics
Post Ipo EquityMay 27, 2025
Amount Raised: $80,000,000
Bambusa Therapeutics

Boston, Massachusetts, United States

Bambusa Therapeutics operates as biotechnology company.

BiotechnologyHealth CareLife ScienceMedical
Series AFeb 14, 2025
Amount Raised: $90,000,000
Monopar

Wilmette, Illinois, United States

Monopar Therapeutics is an emerging biopharmaceutical company focused on developing orphan oncology compounds.

BiopharmaBiotechnologyDeveloper ToolsHealth CareOncologyTherapeutics
Post Ipo EquityDec 20, 2024
Amount Raised: $40,000,000
Palvella Therapeutics

Wayne, Pennsylvania, United States

Palvella Therapeutics focuses on relentlessly and selflessly serving abandoned patient populations with therapies.

BiotechnologyHealth CareLife ScienceTherapeutics
Post Ipo EquityDec 13, 2024
Evommune

Palo Alto, California, United States

Evommune is a biotechnology company that develops therapeutics that halt progressive disease and address their symptoms.

BiotechnologyHealth CareLife Science
Series COct 31, 2024
Amount Raised: $115,000,000
Inhibikase Therapeutics

Atlanta, Georgia, United States

Inhibikase Therapeutics is a developer of cellular Abelson tyrosine kinase inhibitors to treat infections and other diseases.

Health CareHealth DiagnosticsTherapeutics
Post Ipo EquityOct 9, 2024
Amount Raised: $110,000,000
Tenax Therapeutics

Chapel Hill, North Carolina, United States

Tenax Therapeutics focuses on identifying and developing treatments that address cardiovascular and pulmonary diseases.

BiotechnologyHealth CareTherapeutics
Post Ipo EquityAug 6, 2024
Amount Raised: $100,000,000
Kala Pharmaceuticals

Waltham, Massachusetts, United States

Kala Pharmaceuticals develops novel treatments for diseases that affect mucosal tissues.

BiotechnologyHealth CareMedicalPharmaceutical
Post Ipo EquityJun 27, 2024
Amount Raised: $12,500,000